Arcutis to Present at the Cowen 41st Annual Health Care Conference

Rhea-AI Summary

Arcutis Biotherapeutics (Nasdaq: ARQT), a late-stage biopharmaceutical company, will present at the Cowen 41st Annual Health Care Conference scheduled for March 1-4, 2021. The presentation will occur on March 1 at 12:20 p.m. PT / 3:20 p.m. ET and will focus on their advancements in immuno-dermatology. Interested parties can access the presentation via webcast on the company’s website, with an archived replay available for 30 days post-conference. Arcutis aims to address unmet needs in dermatological treatments, highlighting their lead candidate for various skin conditions.

WESTLAKE VILLAGE, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Arcutis management will participate in a virtual presentation during the Cowen 41st Annual Health Care Conference taking place March 1-4, 2021.

Details for the presentation are as follows:
        Cowen 41^st Annual Health Care Conference
        Presentation Date: Monday, March 1, 2021
        Presentation Time: 12:20 p.m. PT / 3:20 p.m. ET

The presentation will be webcast and may be accessed at the “Events & Presentations” section of the Company’s website at https://investors.arcutis.com/events-and-presentations. Arcutis will maintain an archived replay of the webcast on its website for 30 days after the conference.

About Arcutis - Bioscience, applied to the skin.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Investors and Media:
Heather Rowe Armstrong
Vice President, Investor Relations & Corporate Communications
harmstrong@arcutis.com
805-418-5006, Ext. 740

FAQ

When is the Arcutis Biotherapeutics presentation at the Cowen Annual Health Care Conference?

The presentation is scheduled for March 1, 2021, at 12:20 p.m. PT / 3:20 p.m. ET.

How can I access the Arcutis presentation during the Cowen Conference?

The presentation will be available via webcast on Arcutis' website and will also have an archived replay for 30 days post-conference.

What is the focus of Arcutis Biotherapeutics?

Arcutis focuses on developing and commercializing treatments for immune-mediated dermatological diseases.

What is the stock symbol for Arcutis Biotherapeutics?

The stock symbol for Arcutis Biotherapeutics is ARQT.

What conditions does Arcutis' lead product candidate aim to treat?

Arcutis' lead product candidate aims to treat plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.